Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuPharma ( (GB:IMM) ) just unveiled an announcement.
ImmuPharma announced that its senior leadership team, including the CEO, COO and CSO, will attend the JP Morgan Healthcare Conference and the Biotech Showcase in San Francisco from 12–14 January 2026. Participation in these high-profile investor and partnering events is intended to strengthen the company’s visibility among global biopharma companies and investors, potentially supporting future strategic collaborations and funding opportunities.
The most recent analyst rating on (GB:IMM) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.
Spark’s Take on GB:IMM Stock
According to Spark, TipRanks’ AI Analyst, GB:IMM is a Neutral.
The score is primarily held down by very weak financial performance (near-zero revenue, persistent losses, and ongoing cash burn alongside negative equity). Technicals add a modest drag due to negative MACD and the price sitting well below key medium-term averages, while valuation is constrained by a loss-making profile and no dividend support.
To see Spark’s full report on GB:IMM stock, click here.
More about ImmuPharma
ImmuPharma PLC is a UK-listed specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio targets autoimmune diseases and anti-infective indications, positioning the firm within niche, high-need areas of the biotech and pharmaceutical markets.
Average Trading Volume: 3,919,781
Technical Sentiment Signal: Hold
Current Market Cap: £31.17M
Learn more about IMM stock on TipRanks’ Stock Analysis page.